There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD39


CD39 Molecule Information

Name:Ectonucleoside triphosphate diphosphohydrolase 1
Target Synonym:ENTPD1;Ecto-ATPDase 1;CD39;Ecto-ATPase 1;NTPDase 1;Ectonucleoside triphosphate diphosphohydrolase 1;CD_antigen=CD39;Ecto-ATP diphosphohydrolase 1;Ecto-apyrase;Lymphoid cell activation antigen
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase ?

CD39 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD9-H5253 Human Human CD39 Protein, Mouse IgG2a Fc Tag
CD9-H52H4 Human Human CD39 / ENTPD1 Protein, His Tag (active enzyme)

CD39 Molecule Synonym Name

CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1

CD39 Molecule Background

CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms,  a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

CD39 References

CD39 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SRF-617 SRF-617 Phase Ⅰ Surface Oncology Cancer Details
IPH-5201 IPH-5201,IPH5201 Phase Ⅰ INSERM, Orega Biotech, AstraZeneca, Innate Advanced solid tumors Details
TTX-030 TTX-030,TTX030 Phase Ⅰ Tizona Therapeutics, Abbvie Cancer Details

This web search service is supported by Google Inc.